VIDEO: Mehran reviews late-breaking science at TCT

ByErik Swain

ByScott Buzby

ByRoxana Mehran, MD

BOSTON — In the Healio video exclusive, Roxana Mehran, MD, discussed late-breaking research presented at TCT 2022, as well as the benefits of convening the meeting in person following the COVID-19 pandemic.

Mehran, who is professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, discussed findings from the SCAAR registry and the SUGAR, EPIC-STEMI, COPS, EXIT-CALC and RIVARAD trials.

Watch the video for more.

Reference:

Hammami R, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session VI, in Collaboration With Circulation. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Mangieri A, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session VI, in Collaboration With Circulation. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Mehta SR, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session VI, in Collaboration With Circulation. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Mehta SR, et al. EuroIntervention. 2022;doi:10.4244/EIJ-D-22-00735.
Omerovic E, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session V, in Collaboration With The Lancet. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Salinas P, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session VI, in Collaboration With Circulation. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).
Vink MA, et al. Late-Breaking Clinical Science in Coronary Artery Disease: Session VI, in Collaboration With Circulation. Presented at: TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Mehran reports receiving institutional research payments or institutional consultant fees from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Applied Therapeutics, Arena, AstraZeneca, BAIM, Bayer, Beth Israel Deaconess, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, Cytosorbents, DSI, Duke University, Element Science, Faraday, Humacyte, Idorsia, Insel Gruppe AG, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, Philips, RenalPro, Vivasure and Zoll; receiving personal fees from CineMed Research and WebMD; and holding less than 1% equity in Applied Therapeutics, Elixir Medical and Stel Controlrad (spouse).

TCT

Read more

VIDEO: Mehran reviews late-breaking science at TCT

Reference:

Related Content